TScan Therapeutics, Inc. (TCRX)
After hours:
| Previous close | 8.81 |
| Open | 8.74 |
| Bid | 8.64 x 200 |
| Ask | 8.76 x 100 |
| Day's range | 8.57 - 8.95 |
| 52-week range | 1.93 - 9.09 |
| Volume | |
| Avg. volume | 211,180 |
| Market cap | 458.32M |
| Beta (5Y monthly) | 0.90 |
| PE ratio (TTM) | N/A |
| EPS (TTM) | -1.36 |
| Earnings date | N/A |
| Forward dividend & yield | N/A (N/A) |
| Ex-dividend date | N/A |
| 1y target est | 11.60 |
ZacksAnaptysBio, Inc. (ANAB) Expected to Beat Earnings Estimates: Can the Stock Move Higher?
AnaptysBio (ANAB) possesses the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
ZacksTScan Therapeutics, Inc. (TCRX) May Report Negative Earnings: Know the Trend Ahead of Q1 Release
TScan Therapeutics (TCRX) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
GlobeNewswireTScan Therapeutics Announces Upcoming Presentations at the 2024 American Society of Clinical Oncology Annual Meeting
WALTHAM, Mass., April 24, 2024 (GLOBE NEWSWIRE) -- TScan Therapeutics, Inc. (Nasdaq: TCRX), a clinical-stage biopharmaceutical company focused on the development of T cell receptor (TCR)-engineered T cell therapies (TCR-T) for the treatment of patients with cancer, today announced the acceptance of two abstracts for poster presentation at the upcoming 2024 American Society of Clinical Oncology (ASCO) Annual Meeting being held May 31 – June 4 in Chicago, IL as well as virtually. Poster Presentati
